CommercialCoverageHigh impact
11.03.18, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Gastroenterology, Oncology, General Surgery·Medical Policy
Effective date
Oct 1, 2025
We identified it
Sep 3, 2026
Summary
Independence Blue Cross has reissued policy 11.03.18 to establish coverage criteria for Endoscopic Submucosal Dissection (ESD) across four clinical scenarios: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy defines specific lesion characteristics, invasion depth thresholds, and lymph node metastasis documentation requirements that must be met for coverage. Billing teams must now ensure claims include proper documentation of lesion staging and use appropriate HCPCS code C9779 for covered procedures.
Action Required
By September 30, 2025: (1) Billing team must update billing system to recognize HCPCS code C9779 as the primary code for all covered ESD procedures (esophageal, gastric, and colorectal lesions); (2) Configure system to require prior authorization for all ESD claims; (3) Create internal checklist requiring documentation of: lesion size, differentiation level (well/moderate), ulceration status, invasion depth staging (AJCC, JES, or NICE classification), and lymph node metastasis risk assessment for each claim; (4) Update encounter templates and billing submission requirements to mandate providers document these specific criteria; (5) Ensure billing staff flag any ESD claims for lesions not meeting size thresholds (esophageal SCC/dysplasia >1.5cm, adenocarcinoma/Barrett >2cm, gastric <3cm, colorectal >2cm) for medical necessity review before submission; (6) Train providers on ESD expertise requirements (1000 upper GI endoscopies or 500 colonoscopies minimum); (7) Establish process to verify procedure site meets facility requirements. Claims submitted without complete lesion staging documentation or for lesions outside specified parameters will be denied.